99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

Launched by FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · May 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called 99mTc-QULIC-5-P1, which is designed to help doctors see prostate cancer more clearly using a special imaging technique called SPECT. The trial aims to find out how safe this agent is and how well it can show areas of cancer in patients whose prostate cancer cells have a specific marker called PSMA. This could help doctors better diagnose and treat prostate cancer.

To participate in this study, you need to be at least 18 years old and have prostate cancer that tests positive for PSMA, meaning your doctor has evidence from tests like MRI or CT scans showing this. Unfortunately, individuals who are pregnant or have certain serious health issues won’t be eligible. If you join the study, you will receive the imaging agent and undergo scans to see how it works in detecting cancer. The trial is currently looking for male participants between the ages of 65 and 74, but others over 18 may also qualify. This research could lead to better ways to diagnose and manage prostate cancer in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. At least 18 years of age.
• • 2. Signed informed consent.
• • 3. Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
• Exclusion Criteria:
• • 1. Patients with PSMA negative expression.
• • 2. Patients with pregnancy.
• • 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
• • 4. Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components.
• • 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.